Erasca and Eli Lilly and Company have signed a clinical trial partnership and supply agreement to evaluate ERAS-007, an oral ERK1/2 inhibitor, in combination with Eli Lilly's anti-EGFR antibody cetuximab (ERBITUX).
The US Food and Drug Administration (FDA) has granted approval to Avacta Group’s Investigational New Drug (IND) application for AVA6000, a new form of doxorubicin.
Moleculin Biotech has received authorisation to begin a Phase Ia clinical trial of its drug, WP1122, in the UK to treat Covid-19.
Pfizer has dosed the first subjects in a Phase I clinical trial to test an influenza vaccine which is developed using mRNA technology.
Hookipa Pharma has signed a clinical collaboration and supply agreement with Merck to assess HB-200 in combination with Keytruda (pembrolizumab) in patients with advanced head and neck squamous cell carcinoma (HNSCC).
EnGeneIC has started dosing in Phase I clinical trial of the world’s first nanocellular technology-based anti-Covid-19 vaccine in healthy adults.
Centivax has inked a strategic collaboration with the US Naval Medical Research Center (NMRC) to carry out Phase I trial of Centi-B9, its SARS-CoV-2 antibody.
A study, conducted by The Institute of Cancer Research, London (ICR) and Paris-based cancer research institute Gustave Roussy, identified that drugs known as PARP inhibitors kill cancer cells with a particular defect in the PBRM1 gene.
Claritas Pharmaceuticals and CMAX Clinical Research have signed an agreement to conduct a Phase 1 clinical study of R-107.
Antengene has announced that China’s National Medical Products Administration (NMPA) has given approval to investigational new drug (IND) application for Phase I clinical trials of ATG-019 (monotherapy or combined with niacin ER) in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.